About Us
Leadership
Investors
Careers
Partnering
News

We discover and deliver next generation cell medicines to improve the lives of patients.

About Us

Our platform technology immune “cloaks” human pluripotent stem cells and their adult derivatives enabling the development of true ‘off-the-shelf’ cell transplantation therapies.

 

Combined with an unparalleled expertise in generating stem cell-derived adult T, NK and B cells, Clade promises to become a leading innovator in developing widely accessible cell medicines.

 

The company is initially focused on harnessing the potential of “cloaked” immune cells for cancer treatment.

Clade scientists in lab

Management

Chad Cowen

Chad Cowan, PhD

Chief Executive Officer,
Co-Founder
Jim Glasheen

Jim Glasheen, PhD

President / Chief Business Officer, Co-Founder
Leandro Vetcher

Leandro Vetcher

Chief Operating Officer,
Co-Founder

Grant Welstead

Grant Welstead, PhD

Executive Director, Disease Biology
Derek Hei

Derek Hei, PhD

Chief Technology Officer

Board

Daniel Vasella, MD

Chairman of the Board

Martin Murphy, PhD

Board Director

Neil White

Board Director

Chad Cowan, PhD

CEO / Board Director

Jim Glasheen, PhD

President / Board Director

Scientific Co-Founders

Deepta Bhattacharya, PhD

Scientific Co-founder

Chris Sturgeon, PhD

Scientific Co-founder

Gustavo Mostoslavsky, MD PhD

Scientific Co-founder

Clinical and Scientific Advisors

Jonathan Gerber, MD

Jerome Ritz, MD

Derrick Rossi, PhD

Investors

Syncona
LifeSci_Venture
Emerson Collective
bristol-myers-squib

Careers

At Clade Therapeutics, we look for exceptional people who thrive in entrepreneurial environments – those who are motivated by achieving something bigger than themselves, in close collaboration with colleagues.

We are proud to offer a robust Total Reward package that includes a competitive base salary, annual cash bonus program, stock options, work/life flexibility, 401(k) with company contribution, and a comprehensive benefits offering that includes a Health Savings Account with generous company contribution.

To view our openings, click here
clade employees in conference room

Core Values

Patients First ​

Proactively and constructively engage to deliver results for those in need

Communication and Respect

Foster open exchange with colleagues and collaborators

Integrity and Excellence

Act honestly and ethically to seek the truth

Partnering

Clade strives to broaden the impact of cell therapies through its proprietary platform. We are eager to partner with others who have complementary capabilities so that together we can discover and deliver new cell medicines for patients in need. Interested in partnering? Contact us at: partnering@cladetx.com

News

Clade Therapeutics Announces the Appointment of Derek Hei, Ph.D., as Chief Technology Officer

March 10, 2022

Dr. Hei has spent over two decades leading manufacturing teams at biotechnology companies and has deep expertise in the cell therapy space CAMBRIDGE, Mass. – March 10, 2022 – Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, today announced the appointment of Derek Hei, Ph.D., as its

Read More »

Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy

November 3, 2021

Clade’s iPSC immune cloaking and differentiation platform technology to address compatibility, durability, reproducibility and scalability of cell therapies CAMBRIDGE, Mass. – November 3, 2021 – Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, today announced it has secured an $87 million Series A financing led by Syncona

Read More »

Chad Cowan, PhD

Chief Executive Officer, Co-Founder

Chad has over 20 years of experience leading cutting-edge research groups and translating early discoveries into therapies. His prior roles include co-founder and Chief Scientific Officer at Sana Biotechnology and co-founder and Head of Research at CRISPR Therapeutics. Chad has also played an early role in the launch of several gene and cell therapy companies including, BlueRock Therapeutics, Vesigen Therapeutics, Metagenomi, and Vita Therapeutics.

Chad received his BA and BS from the University of Kansas. He received his Ph.D. from the University of Texas Southwestern. In 2006 he was named a Stowers Medical Investigator. In 2008, he became a Professor at Harvard University, Harvard Medical School, and the Harvard Stem Cell Institute, where he led academic research groups and taught.

Jim Glasheen, PhD

President / Chief Business Officer, Co-Founder

Over the past 25 years, Jim led efforts to translate biomedical innovations into broader societal impact as an academic, a strategic consultant, a venture investor, and an executive. Previously, he was co-founder and founding President and CEO of Atalanta Therapeutics, Executive Vice Chancellor at UMASS Medical School, co-lead of Life Science Practice at Technology Partners Venture Capital, and a leader within the Pharmaceutical and Medical Products practice at McKinsey & Company. His training includes a post-doctoral fellowship at University of California, Berkeley, a PhD from Harvard University, a Deutscher Akademischer Austauschdienst Fellowship at Universität des Saarlandes and a BS from Duke University.

Leandro Vetcher

Chief Operating Officer, Co-Founder

Leandro has over 15 years of leadership experience in early-stage life sciences investments, biotech company formation and growth, management of global research organizations, and business development. He knows how to effectively accelerate early opportunities by leveraging modest funding into key milestones that can support larger subsequent investments, operationalize every aspect concerning the launch and growth of a biotech company, develop and influence corporate and R&D strategy, and can design innovative partnering with universities and companies. 

Leandro’s prior roles included VP of Research Operations at Sana Biotechnologies, business development lead for the Blavatnik Biomedical Accelerator at Harvard University, co-founder of Green Pacific Biologicals and Keclon SA, and research and business development positions at Kosan Biosciences and Johnson & Johnson’s M&A team. He has seven peer-reviewed publications and three issued patents. Leandro earned an MBA from the Massachusetts Institute of Technology, a Masters in Biotechnology from Columbia University, and a Licentiate in Biotechnology from Rosario National University in Argentina. 

Grant Welstead, PhD

Executive Director, Disease Biology

Grant is an experienced cell engineer with deep expertise in the development of engineered cell medicines for oncology. Prior to Clade, Grant led several programs at Editas Medicine that were focused on the development of CRISPR gene-edited T cells and iPSC-derived NK cells. As the 8th hire in 2014, he was also an integral part of building a strong company culture that supported the transition of Editas from a 10-person, series A startup to a publicly traded, clinical stage company.

Grant was awarded his Ph.D. from the Department of Medical Biophysics at the University of Toronto and received his Bachelor of Science from McGill University in Montreal, majoring in Microbiology and Immunology. After his doctorate, Grant was a NIH postdoctoral fellow in the laboratory of Rudolf Jaenisch at the Whitehead Institute for Biomedical Research where he studied epigenetics in stem cells, cancer and cellular reprogramming.

Derek Hei, PhD

Chief Technology Officer

Derek has deep expertise in the cell therapy space and over two decades of experience leading manufacturing teams at biotechnology companies. He previously served as Senior Vice President (SVP) of Preclinical and Clinical Manufacturing, Cell and Gene Therapies at Vertex Pharmaceuticals, where he was responsible for leading chemistry, manufacturing, and controls (CMC) activities for multiple cell and gene therapy programs. Prior to his time at Vertex, Derek served as SVP of Manufacturing, Quality, and Regulatory at BlueRock Therapeutics as well as BlueRock’s Chief of Manufacturing and Technical Operations. In these roles, Derek managed the design and construction of a state-of-the art cleanroom facility to support the derivation of gene-edited induced pluripotent stem cell (iPSC) lines and the production of current good manufacturing practices (cGMP)-compliant cell therapies for clinical trials. He also previously served as SVP of Clinical Manufacture, Quality, and Regulatory at Cellular Dynamics International, and established and grew Waisman Biomanufacturing’s initial facility as the company’s Director. Derek earned his Ph.D. in biochemical engineering from the University of California, Berkeley and his Bachelor of Science in chemical engineering from the University of Wisconsin-Madison.

Daniel Vasella, MD

Chairman of the Board

After the foundation of Novartis in 1996 he led the company for 17 years as CEO (1996-2010) and Chairman of the Board of Directors (1999-2013). Since 2013 Dr. Vasella is Honorary Chairman of the Board of Directors for Novartis AG.

Before the Novartis merger, Dr. Vasella was CEO of Sandoz Pharma Ltd. and a member of the Sandoz Group Executive Committee. From 1988 to 1992, he worked for Sandoz Pharmaceuticals Corporation in the United States, prior to which he held a number of medical positions in Switzerland. He graduated with an M.D. from the University of Bern and completed executive training at Harvard Business School.  Dr. Vasella also trained as psychoanalyst and executive coach.  He was awarded an honorary doctorate from the Faculty of Medicine at the University of Basel and the Harvard Business School Alumnus Award and many other distinctions.

Dr. Vasella is a member of the board of directors of PepsiCo, Inc., the American Express Company and biotech companies. He is also a foreign honorary member of the American Academy of Arts and Sciences, as well as of various cultural establishments.

Daniel Vasella is married and father of three children.

Martin Murphy, PhD

Board Director

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Quell and Anaveon and is a Director of Autolus, Resolution, Neogene Therapeutics and Clade Therapeutics. He was previously Chairman of Blue Earth Diagnostics, which Syncona sold to Bracco Imaging for $476 million in 2019.

Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.

Neil White

Board Director

Neil has over 10 years of experience in the life sciences sector, spanning investment banking and leadership roles. Previously he worked in Capital Markets at Bank of America Merrill Lynch, and in Healthcare Mergers & Acquisitions advisory at Torreya Partners and Perella Weinberg Partners. He is now an investment manager in the Health Team of Emerson Collective, focused on investing in and supporting the clinical translation of novel treatments in oncology and improving the lives of cancer patients. Neil received his MSc (Res) from the University of Oxford and BSc (Hons) from the University of Toronto. 

Deepta Bhattacharya, PhD

Scientific Co-founder

Deepta Bhattacharya received his Ph.D. from the University of California, Berkeley, where he studied the NF-kB transcription factor’s role in survival and B cell class switching. For his postdoctoral fellowship, he trained at Stanford University, studying the cell biology of hematopoietic stem cells and their differentiated progeny. In 2008, he launched his lab at Washington University in St. Louis, first as an Assistant Professor and then as a tenured Associate Professor. Dr. Bhattacharya returned in 2017 to his birthplace of Tucson to join the Department of Immunobiology, where his lab continues to study both stem cells and antibody responses to infections and vaccines.

Chris Sturgeon, PhD

Scientific Co-founder

Dr. Sturgeon is an Associate Professor at the Icahn School of Medicine at Mount Sinai. He earned a Ph.D. in Biochemistry on cell cycle regulation at the University of British Columbia. Dr. Sturgeon completed postdoctoral studies at the McEwen Centre for Regenerative Medicine at the University of Toronto, studying pluripotent stem cell-derived hematopoiesis. Prior to joining Mount Sinai, Dr. Sturgeon was a member of the Washington University School of Medicine Hematology Division. His studies focus on characterizing the signal pathways that control human pluripotent stem cell differentiation towards hematopoietic stem/progenitors, and how this impacts the development and function of immune cells.

Gustavo Mostoslavsky, MD PhD

Scientific Co-founder

Dr. Mostoslavsky received his MD from the University of Tucuman in Argentina and his Ph.D. from the Hebrew University in Jerusalem, Israel. His longstanding interest in basic science and regenerative medicine brought him to Harvard Medical School to pursue postdoctoral studies with stem cells and gene therapy. In 2008 Dr. Mostoslavsky opened his lab at Boston University. He is currently an Associate Professor of Medicine in the Section of Gastroenterology in the Department of Medicine at Boston University School of Medicine. His main research interests are stem cells, disease modeling, regenerative medicine, gene correction, and lentiviral vectors as gene transfer tools. Dr. Mostoslavsky is a founder and Co-Director of the BU Center for Regenerative Medicine (CReM).

Jonathan M. Gerber, MD

Jonathan M. Gerber, MD received his undergraduate degree in Biology from Johns Hopkins University in Baltimore, Maryland, where he was inducted into Phi Beta Kappa.  He received his MD from the Johns Hopkins School of Medicine, where he was inducted into Alpha Omega Alpha. He then completed residency in Internal Medicine and fellowship in Hematology, both also at Johns Hopkins. Upon completion of his training, he served on the faculty of the Johns Hopkins School of Medicine for 5 years, in the Division of Hematology. 

Dr. Gerber left Johns Hopkins to found and lead the Leukemia Program at the newly created Levine Cancer Institute (LCI) of the Carolinas HealthCare System in Charlotte, North Carolina. He also helped start the Blood and Marrow Transplantation (BMT) Program at LCI, performing the first allogeneic BMT in an adult in the city of Charlotte in March of 2014.  Additionally, he oversaw the creation of a new inpatient service line and served as the Medical Director of the Department of Hematology and a clinical faculty member at the University of North Carolina School of Medicine at Chapel Hill during his time in Charlotte. 

Dr. Gerber then joined the University of Massachusetts Medical School and UMass Memorial Health Care in 2018 , where he serves as the Chief of Hematology & Oncology and the Medical Director of the Cancer Center.  He holds the Eleanor Eustis Farrington Chair in Cancer Research.

Dr. Gerber’s clinical interests include leukemia and related hematologic conditions, as well as BMT.  He is a translational laboratory researcher and an early phase clinical trial investigator.  His research focuses on improving the identification and targeting of the stem cells at the root of leukemia and other clonal hematologic diseases, with the goal of personalizing therapy and developing better treatments that are more effective and less toxic.  He has published numerous articles in his field, presented his research findings at national & international meetings, and served as a reviewer for the National Institutes of Health and prominent journals.  Dr. Gerber has also received many grants and awards for his research, including funding from the Leukemia & Lymphoma Society and Swim Across America Foundation, as well as the Johns Hopkins University School of Medicine Clinician Scientist and the Passano Foundation Physician Scientist awards.  His work has resulted in several U.S. patents and has been translated into clinical trials.   

Dr. Gerber is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO). He currently is a member of the ASH Committee on Practice and the Subcommittee on Precision Medicine; and he previously served on the ASCO Cancer Research and Education committees.  Dr. Gerber has served as a member of the board of the Charlotte, NC chapter of the Leukemia & Lymphoma Society and has been an active fundraiser with the Swim Across America Foundation.

Jerome Ritz, MD

Dr. Ritz is currently Professor of Medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Brigham and Woman’s Hospital and Harvard Medical School.

His research laboratory focuses on the assessment of donor immune function after allogeneic hematopoietic stem cell transplantation (HSCT) and characterization of immune mechanisms responsible for graft versus leukemia (GVL) and graft versus host disease (GVHD). These laboratory studies have led to new clinical approaches to enhance GVL and prevent or treat GVHD. His lab also studies other cellular therapies for hematologic malignancies including CAR-T cells and activated NK cells. Working closely with clinical collaborators he has developed approaches to precisely characterize the effects of these treatments on immune function in vivo. These results are correlated with clinical outcomes such as response and toxicity to develop a better understanding of the immunologic mechanisms that contribute to these outcomes.

Dr. Ritz is also the Executive Director of the Connell and O’Reilly Families Cell Manipulation Core Facility at DFCI. This GMP cell manufacturing facility supports both adult and pediatric hematopoietic stem cell transplant programs at DFCI, Brigham and Women’s Hospital and Boston Children’s Hospital and also provides a variety of novel cellular products for patients enrolled on clinical trials at DFCI and affiliated hospitals. This facility recently expanded to include 15 cleanrooms available to manufacture a variety of cellular products including genetically modified stem cells, genetically modified immune cells, regulatory T cells, natural killer cells and other complex cellular products. This facility is a critical resource for both academic investigators and industry sponsors interested in developing innovative cellular therapies.

Derrick Rossi, Ph.D.

Derrick Rossi received his B.Sc. and M.Sc. degrees from the University of Toronto, Canada in the 1990s, and his Ph.D. from the University of Helsinki, Finland, followed by post-doctoral training at Stanford University. Dr. Rossi is an Associate Professor in the Department of Pediatrics at Harvard Medical School. He is also an investigator in the Program in Cellular and Molecular Medicine at Boston Children’s Hospital, where he holds a Boston Children’s Hospital Pediatrics Chair. Dr. Rossi has been a principal faculty member of the Harvard Stem Cell Institute since 2008.

Dr. Rossi’s lab at Harvard Medical School focuses on diverse aspects of hematopoietic stem cell biology, including how aging of the stem cell compartment contributes to disease pathogenesis and aging-associated hematopoietic decline. His efforts in the development of cutting edge technologies and new therapeutic strategies are at the forefront of regenerative medicine and biotechnology. Discoveries made in Dr. Rossi’s lab have led to the formation of several leading biotechnology companies. In 2010, Derrick Rossi founded Moderna Therapeutics, a clinical-stage company focused on developing modified-mRNA therapeutics. In 2015, Dr. Rossi co-founded Intellia Therapeutics, a Cambridge-based company focused on developing CRISPR/Cas9 based therapeutics. In 2016, he co-founded Magenta Therapeutics, which is focused on transforming transplantation medicine. Dr. Rossi is currently serving as the founding CEO of Convelo Therapeutics where he leads a team that is developing regenerative therapies for demyelination diseases of the central nervous system.

Time magazine cited Dr. Rossi’s discovery of modified-mRNA reprogramming as one of the top ten medical breakthroughs of 2010. Time magazine also named Dr. Rossi as one of the “People Who Mattered” in 2010, and as one of the 100 Most Influential People in the world (Time 100) in 2011.